Early Risk Identification of Sepsis During Induction Chemotherapy in Newly Diagnosed AML : A Nomogram‐Based Tool
Cancer Medicine · 2026
DOI: 10.1002/cam4.72138 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Medicine, 2026. Verfasst von Cui-Ying Gu und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China. Hauptthemen laut MEDLINE: Nomograms, Induction Chemotherapy, Leukemia, Myeloid, Acute, Sepsis. Die Arbeit nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Guangzhou Municipal Science and Technology Project, Cultivation Project for the National Natural Science Foundation of China (NSFC) of the Third Affiliated Hospital, Sun Yat-sen University, National Natural Science Foundation of China.
Themen: Onkologische Pflege, Sepsis
Abstract (Originalsprache)
Background
Patients with acute myeloid leukemia (AML) experience severe infections frequently during and after chemotherapy. The purpose of this study was to develop an early risk assessment tool to identify newly diagnosed AML patients at high risk of developing sepsis during the early phase of induction chemotherapy.
Methods
The records of 192 newly diagnosed AML patients from February 2017 to December 2023 at our institution were retrospectively reviewed. Kaplan–Meier survival analysis was performed to explore the prognosis difference between groups with or without sepsis. Mann–Whitney U test, Chi‐square test, and multivariable logistic regression analysis were used to identify independent risk factors and establish a nomogram for early risk stratification of sepsis. The predictive accuracy of the nomogram was evaluated using the area under the curve (AUC), calibration curves, and concordance index (C‐index). The nomogram is intended for application on days 3–5 of induction chemotherapy.
Results
Multivariate logistic regression identified TP53 mutation, elevated aspartate aminotransferase (AST) and C‐reactive protein (CRP) at diagnosis, increased procalcitonin (PCT), and higher urea levels post‐induction as independent risk factors for sepsis progression. The bootstrap‐corrected AUC was 0.892 (C‐index 0.892). The bias‐corrected calibration curve was close to the ideal line, demonstrating strong consistency between actual observations and predictions. Patients with sepsis experienced a poorer prognosis ( p < 0.001) both at 1‐year and 5‐year survival rates. The incidence rates of pneumonia and invasive fungal infection were higher in the sepsis group.
Conclusions
We developed a nomogram for early identification of sepsis risk in newly diagnosed AML patients during their initial induction chemotherapy. This tool may assist clinicians in identifying patients requiring close monitoring and intensive supportive care.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Hematology, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.
ORCID-Profile: Jia-Jun Liu
Förderung
- Guangzhou Municipal Science and Technology Project
- Cultivation Project for the National Natural Science Foundation of China (NSFC) of the Third Affiliated Hospital, Sun Yat-sen University
- National Natural Science Foundation of China
Zitieren
APA
Gu, C. Y., Feng, Y. S., He, Q. S., Zhang, L., & Liu, J. J. (2026). Early Risk Identification of Sepsis During Induction Chemotherapy in Newly Diagnosed AML : A Nomogram‐Based Tool. Cancer Medicine. https://doi.org/10.1002/cam4.72138
Vancouver
Gu CY, Feng YS, He QS, Zhang L, Liu JJ. Early Risk Identification of Sepsis During Induction Chemotherapy in Newly Diagnosed AML : A Nomogram‐Based Tool. Cancer Medicine. 2026. doi:10.1002/cam4.72138
BibTeX
@article{Gu2026,
author = {Gu, Cui-Ying and Feng, Ya-Shu and He, Qing-Song and Zhang, Ling and Liu, Jia-Jun},
title = {Early Risk Identification of Sepsis During Induction Chemotherapy in Newly Diagnosed AML : A Nomogram‐Based Tool},
journal = {Cancer Medicine},
year = {2026},
doi = {10.1002/cam4.72138}
}
EUVIMED